Description
VIGAMOXI® is indicated for surgical prophylaxis, bacterial keratitis, corneal ulcers, bacterial blepharitis, ophtalmia neonatorum (ocular infection of the newborn), and in the treatment of bacterial conjunctivitis caused by susceptible strains of the following microorganisms:
Gram-positive aerobes
Gram-negative aerobes
Other micro-organisms
Corynebacterium species *
Acinetobacter lwoffii *
Chlamydia trachomatis
Micrococcus luteus *
Haemophilus influenzae
Staphylococcus aureus
Haemophilus parainfluenzae *
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus hominis
Staphylococcus warneri *
Streptococcus pneumoniae
Streptococcus viridans
* The efficacy of VIGAMOXI® against these microorganisms was studied in at least 10 infections.
VIGAMOXI® has excellent bioavailability and improved penetration which results in a decrease in the development of bacterial resistance; maintains effective concentrations in the aqueous humor of patients undergoing cataract surgery.
VIGAMOXI® does not contain preservatives (it is free of benzalkonium chloride) and is formulated with a pH of 6.8 for greater comfort and better solubility.
VIGAMOXI® is an antibacterial agent of the fluoroquinolone class, extremely powerful with a broad spectrum and bactericidal action, both in the growth phase and in the stationary phase of bacteria. It has in vitro activity against a wide range of gram-positive and gram-negative microorganisms, anaerobes, acid-fast bacilli and atypical bacteria such as Mycoplasma, Chlamydia and Legionella; it is effective against bacteria resistant to ß-lactams and macrolides, and in studies in infected animals, it has been shown to have high antimicrobial activity in vivo.
Reviews
There are no reviews yet.